Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

a study on Kidney Disease

Summary

Eligibility
for people ages 10-65 (full criteria)
Location
at Orange 5379513, California 5332921 and other locations
Dates
study started
study ends around

Description

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Official Title

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Keywords

Proteinuric Kidney Disease, APOL1-mediated kidney disease (AMKD), Counterfeit Drugs, VX-147

Eligibility

You can join if…

Open to people ages 10-65

You CAN'T join if...

Other protocol defined Inclusion/Exclusion criteria apply.

Locations

  • UCI Center for Clinical Research accepting new patients
    Orange 5379513 California 5332921 92868 United States
  • UCLA Division of Nephrology completed
    Los Angeles 5368361 California 5332921 90095 United States
  • UCLA Lundquist Institute at Harbor-UCLA Medical Center accepting new patients
    Torrance 5403022 California 5332921 90502 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Vertex Pharmaceuticals Incorporated
ID
NCT05312879
Phase
Phase 2/3 Kidney Disease Research Study
Study Type
Interventional
Participants
Expecting 466 study participants
Last Updated
Contact us about this trial